News: Translational Research and Interventional Oncology Research Program

Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).

Researchers at Vanderbilt University Medical Center and Case Western Reserve University in Cleveland have been awarded a five-year, $3.3 million grant by the National Cancer Institute to apply artificial intelligence (AI) to help customize treatment for oral cancer patients.

Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.

Christine Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, has been named incoming chair of GO2 Foundation’s Scientific Leadership Board (SLB).

Vivian Weiss, MD, PhD, has been named a 2020 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Michael Savona, MD, professor of Medicine and Cancer Biology, and director of Hematology Research at Vanderbilt-Ingram Cancer Center, has received a competitive grant award from the Edward P. Evans Foundation.

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

The nature of childhood cancer is different than adult cancer, and so is the approach to treatment.